PFAS Water Infrastructure Financing: Federal and State Funding Programs

Scale of PFAS Infrastructure Costs

The EPA estimated that meeting the 2024 PFAS drinking water MCLs will require $1.5–$2.5 billion annually in new treatment infrastructure nationally. For individual utilities, treatment costs range from under $100,000 for small systems installing point-of-entry GAC to over $50 million for large utilities requiring advanced treatment for multiple entry points.

The financial burden falls most heavily on utilities in states with widespread PFAS contamination (including states near military bases and industrial PFAS users), small and medium systems with limited bonding capacity and rate base, and utilities serving low-income communities where rate increases face the most resistance.

Federal Infrastructure Funding Sources

The Infrastructure Investment and Jobs Act (IIJA) of 2021 provided $15 billion specifically for lead service line replacement and emerging contaminants through the Drinking Water State Revolving Fund (DWSRF), with $4 billion reserved as grants for disadvantaged communities. PFAS treatment qualifies as an emerging contaminant project eligible for this funding.

EPA’s Water Infrastructure Finance and Innovation Act (WIFIA) program provides low-interest federal loans for large water infrastructure projects above $20 million. PFAS treatment projects at large utilities can access WIFIA financing at below-market interest rates, reducing long-term financing costs for treatment system capital expenditures.

State Programs and Utility Strategies

Many states have created PFAS-specific infrastructure programs funded by their DWSRF allocation and, in some cases, by PFAS settlement funds. Michigan’s PFAS Community Response Team, for example, provides technical and financial assistance to contaminated communities through state-funded programs.

Utilities pursuing PFAS financing should develop comprehensive capital improvement plans documenting PFAS compliance needs, estimated costs, and implementation timelines. Demonstrating that treatment selection reflects least-cost analysis and that disadvantaged community status qualifies for grant (rather than loan) funding maximizes access to available federal and state assistance programs.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top